2 mg/ml
Sponsors
Odense University Hospital, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Friedrich-Schiller-Universitaet Jena, Friedrich-Schiller-Universitaet Jena, Polska Grupa Badawcza Chloniakow
Conditions
Advanced dedifferentiated liposarcomaCows' milk allergyGERDHodgkin lymphomaPatients with sepsis or septic shockcurrently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.
Phase 2
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
CompletedCTIS2024-511361-11-00
Start: 2022-03-25End: 2025-11-21Target: 209Updated: 2025-07-04
Epirubicin for the Treatment of Sepsis & Septic Shock
CompletedCTIS2024-515776-12-00
Start: 2022-06-30End: 2025-05-21Target: 45Updated: 2024-10-01
Phase 3
Behandling af gastroesofageal refluks sygdom hos spædbørn- et randomiseret studie
Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled Trial
RecruitingCTIS2022-502770-16-00
Start: 2025-10-27Target: 96Updated: 2025-03-07
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
Not yet recruitingCTIS2026-525263-41-00
Target: 370Updated: 2026-05-29